Rachel Haurwitz, Caribou Biosciences CEO

‘Look be­fore you leap’: Cari­bou to start Ph1 au­toim­mune study of CAR-T ther­a­py

Just like oth­er cell ther­a­py com­pa­nies, Cari­bou Bio­sciences is en­ter­ing the au­toim­mune dis­ease field.

The Berke­ley, CA-based biotech dis­closed Thurs­day af­ter­noon that the FDA cleared it to be­gin a clin­i­cal tri­al of its off-the-shelf cell ther­a­py in lu­pus, and Cari­bou ex­pects to start the Phase 1 study by the end of 2024.

Cari­bou is join­ing the herd of com­pa­nies study­ing cell ther­a­py for au­toim­mune con­di­tions, where in­ter­est has ex­plod­ed af­ter an aca­d­e­m­ic re­search group led by Georg Schett from the Friedrich-Alexan­der Uni­ver­si­ty Er­lan­gen-Nürn­berg re­port­ed strik­ing re­sults in a small group of pa­tients with lu­pus and oth­er au­toim­mune dis­or­ders. Oth­er com­pa­nies that have en­tered in­to the au­toim­mune cell ther­a­py field re­cent­ly in­clude Nkar­ta and CRISPR Ther­a­peu­tics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.